A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer

被引：1
|
作者：
Gill, Harpaul S. [1 ]
Ramalingam, Suresh S. [1 ]
机构：
[1] Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, 1365 Clifton Rd NE,Bldg C,Suite 4014, Atlanta, GA 30322 USA
来源：
CANCER | 2019年 / 125卷 / 13期
关键词：
durvalumab; immune checkpoint inhibition; NSCLC; PACIFIC trial; stage III NSCLC; RANDOMIZED PHASE-III; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; CONSOLIDATION DOCETAXEL; THORACIC RADIOTHERAPY; TRIAL; CHEMOTHERAPY; COMBINATION; CARBOPLATIN;
D O I：
10.1002/cncr.31996
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Overall survival data from the PACIFIC trial have reaffirmed earlier US Food and Drug Administration approval of durvalumab in patients with stage III non-small cell lung cancer. In the current commentary, the authors provide a brief historical perspective on stage III disease as well as a further analysis of the strengths and weaknesses of the trial.
引用
收藏
页码：2148 / 2153
页数：6
相关论文
共 50 条
  • [21] Chemotherapeutic issues in the management of unresectable stage III non-small cell lung cancer
    Socinski, MA
    Rosenman, JG
    SEMINARS IN ONCOLOGY, 2005, 32 (02) : S18 - S24
  • [22] Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer
    Bunn, Paul A., Jr.
    Gaspar, Laurie E.
    Weyant, Michael J.
    Mitchell, John D.
    CANCER, 2016, 122 (05) : 674 - 675
  • [23] Combined modality therapy for unresectable stage III non-small cell lung cancer - New chemotherapy combinations
    Belani, CP
    CHEST, 2000, 117 (04) : 127S - 132S
  • [24] Stage III Non-small Cell Lung Cancer
    Rusch, Valerie W.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (05) : 727 - 735
  • [25] Comparison of chemoradiation and radiation therapy alone in patients with stage III unresectable non-small cell lung cancer
    Ahn, S
    Kim, Y
    Kim, K
    Na, K
    Kim, Y
    Bom, H
    Park, K
    LUNG CANCER, 2005, 49 : S164 - S165
  • [26] Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice
    Furuhashi, K.
    Hataji, O.
    Nakamura, Y.
    Suzuki, Y.
    Sakaguchi, T.
    Ito, K.
    Fujiwara, K.
    Nishii, Y.
    Taguchi, O.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1104 - S1104
  • [27] Management of unresectable stage III non-small cell lung cancer: The role of combined chemoradiation
    Penland, SK
    Socinski, MA
    SEMINARS IN RADIATION ONCOLOGY, 2004, 14 (04) : 326 - 334
  • [28] Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cancer
    Gaspar, LE
    CURRENT OPINION IN ONCOLOGY, 2001, 13 (02) : 110 - 115
  • [29] Patterns of care for stage III non-small cell lung cancer in Australia
    Parente, Phillip
    Chan, Bryan A.
    Hughes, Brett G. M.
    Jasas, Kevin
    Joshi, Rohit
    Kao, Steven
    Hegi-Johnson, Fiona
    Hui, Rina
    McLaughlin-Barrett, Sara
    Nordman, Ina
    Stone, Emily
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (03) : 93 - 100
  • [30] Consolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care
    Wu, Fang
    Zeng, Yue
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (10) : 2853 - 2855
12345